Can Facet Arthroplasty Outperform TLIF for Spondy?

Key Takeaways

• TOPS achieved 85% composite success vs 64% TLIF.
• ODI improvement ≥15 points in 93% TOPS vs 81% TLIF.
• Motion preserved: 3.86° flexion‑extension at 24 months.
• Reoperation rates lower for TOPS (5.9%) versus TLIF (8.8%).
• Study limited to 24‑month follow‑up, single‑level L4‑5.

Summary

A prospective, multicenter FDA IDE trial compared the Total Posterior Spine (TOPS) facet arthroplasty system with traditional transforaminal lumbar interbody fusion (TLIF) in 249 patients with single‑level grade I degenerative spondylolisthesis. At 24 months, TOPS achieved an 85% composite clinical success rate versus 64% for TLIF, driven by higher ODI improvements and comparable pain relief. The study also demonstrated preserved segmental motion (≈3.86°) and slightly lower reoperation rates for the motion‑preserving cohort. These findings suggest that facet replacement can match or exceed fusion outcomes while maintaining spinal mobility.

Pulse Analysis

Degenerative lumbar spondylolisthesis has traditionally been treated with decompression plus fusion, most commonly TLIF, because fusion guarantees segmental stability. However, fusion eliminates motion and has been linked to adjacent‑segment disease, prompting interest in motion‑preserving technologies. The TOPS system, a posterior facet replacement, entered the spotlight after a rigorous FDA‑sponsored IDE trial demonstrated that preserving the posterior column can be both safe and effective, positioning it as a credible challenger to the fusion paradigm.

The trial’s primary endpoint—composite clinical success—favored TOPS, with 85% of patients meeting stringent criteria versus 64% for TLIF. Functional outcomes reinforced this advantage: 93% of TOPS recipients achieved a ≥15‑point ODI improvement compared with 81% in the fusion group, while back‑pain VAS gains were numerically higher, though not statistically significant. Importantly, radiographic analysis confirmed that TOPS maintained near‑baseline flexion‑extension range (≈3.86°) over two years, validating the device’s biomechanical premise of motion preservation without compromising stability. Reoperation rates were modestly lower for TOPS, suggesting early durability.

For spine surgeons, these data signal a shift toward individualized treatment algorithms that weigh motion preservation against the traditional benefits of fusion. While the 24‑month horizon limits conclusions about long‑term adjacent‑segment protection, the trial provides a high‑level evidence base for adopting facet arthroplasty in carefully selected patients. Market adoption will depend on longer follow‑up, reimbursement pathways, and surgeon familiarity with the learning curve. Nonetheless, the TOPS trial marks a pivotal moment, indicating that the era of automatic fusion for every lumbar slip may be giving way to nuanced, motion‑conscious strategies.